RIGHT. ON TIME. — India's Trusted Nuclear Medicine, Radiotherapy & Oncology Partner for the last 40 years

+91 11 4077 6666 saxsons@saxsons.com

23 Jul 2026Peer-ReviewedPubMedClinical TrialEuropean urology · 2026

Re: Robert M. Meier, Nima Aghdam, Alan C. Beckman et al. 10-yr Survival and Toxicity Outcomes of Stereotactic Body Radiotherapy for Prostate Cancer: A Nonrandomized Clinical Trial. Eur Urol In press. http://dx.doi.org/10.1016/j.eururo.2026.04.029.

Kim JS, Chang AR, Kim JH.

Read on PubMed →doi:10.1016/j.eururo.2026.06.027 →

Identifiers

PubMed ID: 42493338

DOI: 10.1016/j.eururo.2026.06.027

Radar topics

Related in the same topic

International journal of clinical oncology · 2026

Clinical indications and implications of metastasis-directed therapy and primary-site treatment in metastatic urothelial carcinoma.

Physical and engineering sciences in medicine · 2026

The use of Perspex-based devices in patient specific quality assurance of Acuros XB plans.

Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer: Research Summary.

Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer: A Randomized Clinical Trial.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique · 2026

Long-term control after stereotactic body radiotherapy for perineal recurrence of prostate cancer after radical prostatectomy and radiotherapy: A case report and review of the literature.

International journal of radiation oncology, biology, physics · 2026

Phase I/II Trial of Durvalumab plus Tremelimumab and Stereotactic Body Radiotherapy for Metastatic Head and Neck Carcinoma.

Search all papers →More SBRT delivery research →